Looking back on his first year as CEO of Organigram, Greg Engel proudly highlights the successful transition of the company from being a low-cost to a high-quality cannabis producer with premium products. He emphasizes Organigram’s close collaboration with both federal and provincial governments, on both the medical and recreational business, as well as the company’s plans for expansion to Europe.
Greg, you took on the role of CEO of Organigram; what inspired the move from traditional pharma into the cannabis niche?
"In the expectation of legalization, Organigram has been working in close collaboration with the federal government and even more intensively with some of the provincial governments."
